Transcription factors have been shown to play a role as "master switch" factors in the programming of hematopoietic cell commitment and differentiation. PU
Hematopoiesis is a complex cascade of events that give rise to terminally differentiated cells from a population of pluripotent progenitors. In order to assess the early events in lineage commitment, hematopoietic progenitor cells can be enriched from normal human bone marrow and peripheral blood by selection with CD34 monoclonal antibody (1) (2) (3) . The CD34+ population represents 1-4% of the mononuclear cells in the bone marrow and retains differentiation potential in vitro and in vivo (1, 4) .
The molecular mechanisms involved in the early events of hematopoietic development have not been fully clarified, but transcription factors play a key role (5) . GATA-1, for example, has been shown to be essential for erythroid development (5, 6) . GATA-1 is expressed at low levels in highly purified CD34+ cells and is gradually upregulated through the terminal stages of erythroid differentiation, while it is downregulated in late progenitor/early differentiated myeloid precursors (7, 8) .
As a possible myeloid counterpart of GATA-1, we investigated the role of PU.1 in human hematopoiesis. PU.1 is expressed in a cell type-specific manner in macrophages, B cells, and early erythroblasts (9, 10) . PU.1 is the product of the protooncogene Spi-1, which was identified at the site of insertional mutagenesis of the Friend and Rauscher virus in murine erythroleukemia (11) . This insertion leads to overexpression of PU.1 and consequently to immortalization of erythroblasts, as confirmed by in vitro studies (12) . Furthermore, PU.1 regulates the tissue-specific expression of the myeloid differentiation-associated genes encoding CD11b and the macrophage-colony-stimulating factor (M-CSF) receptor (c-fms), through binding sites in their promoter regions (13, 14) . In addition, PU.1 plays a role in the activation of immunoglobin promoters and enhancers in B cells (15) (16) (17) . These data suggest a role for PU.1 as a "master switch" in hematopoietic cell development, as already shown for GATA-1 in erythroid development (5, 6 Proc. Natl. Acad. Sci. USA 91 (1994) 7933 unit/ml), GM-CSF (10 ng/ml), iron-saturated transferrin (1 mg/ml), and erythropoietin (3 units/ml) (medium I) or of 30%6 heat-inactivated FBS, 5% serum-containing conditioned medium from phytohemagglutinin-stimulated lymphocytes, and 1% bovine serum albumin (medium II) (StemCell Technologies, Vancouver, BC, Canada). Colonies (>50 cells) were enumerated by phase-contrast microscopy after 14 (18) and were purified by PAGE. The sequences of the oligonucleotides were as follows: wild-type PU.1 site in the CD11b promoter (sense strand), 5'-GCTGAAAGAAGGGCAGAAAAGGAGAAG-TAG-3' (CD11b-PU.1); same PU.1 site, with Ml mutation (13), 5'-GCTCAAAGAAGGGCAGCCCGGGAGAAG-TAG-3' (CDllb-Ml mutant); wild-type PU.1 site in the simian virus 40 (SV40) enhancer, 5'-TGAAATAACCTCT-GAAAGAGGAACTTGGTTAGGTA-3' (SV40-PU.1); same site with scrambled sequence, 5'-GTATGTAATGCAA-CAATATGGTAGCGTACAGTAGA-3' (SV4O-scrambled).
Equimolar amounts ofcomplementary strands were annealed in 2 mM Tris HCl, pH 7.5/1 mM MgCl2/5 mM NaCl/0.1 mM dithiothreitol. Designated members of the Ets family were translated in vitro with the TnT coupled reticulocyte lysate translation system (Promega) and their ability to bind specifically to a 32P-labeled double-stranded oligonucleotide containing the CDllb-PU.1 site was assessed as described (13) .
Competition Experiments. Day 0 CD34-enriched cells were incubated at 2.5 x 106 per ml in RPMI 1640 medium with 10%1
heat-inactivated FBS for 5 hr at 37°C in a humidified 5% CO2 atmosphere in the presence of no added oligonucleotide (control) or in the presence of 10 ,uM double-stranded oligonucleotide. Cells were then cultured in methylcellulose as described above. In the experiments evaluating the effects of the delayed addition of the oligonucleotides, the cells were cultured for 2, 4, or 6 days in the liquid medium described above prior to the addition of the double-stranded oligonucleotides, and then plated in methylcellulose. (4, 23) , were induced to differentiate along the myeloid end erythroid pathways. Total RNA was extracted at various times of the differentiation processes and PU.1 expression was evaluated in relation to GATA-1 and to several well-known myeloid markers (Fig. 1) by RT-PCR. PU.1 and GATA-1 were reciprocally regulated during differentiation of CD34+ cells. While GATA-1 was dramatically upregulated only in the erythroid pathway, as previously described (7), PU.1 was selectively upregulated at day 1 of GM-CSF treatment, preceding the upregulation of two of its target genes, the myeloid-specific leukocyte integrin CD11b and the M-CSF receptor, that took place between days 4 and 6 ( Figs. 1 and 2 ). In three independent experiments, PU.1 mRNA remained stable through day 11 of erythroid culture, consistent with the findings of Galson et al. (10) in erythroid bone marrow precursors and cell lines.
RESULTS
The presence of CD11b, CD18, and M-CSF receptor transcripts in the day 0 CD34-enriched population indicated that this population contained a number of already- CD34 and CD38 antibodies. The resulting CD34+CD38-population was also positive for PU.1 mRNA, and the relative amount of PU.1 increased with the acquisition of a more mature phenotype, CD34-CD38+ (data not shown). To evaluate whether PU.1 was expressed in a totipotent cell capable of differentiating into hematopoietic and nonhematopoietic lineages, we studied the murine embryonic stemcell system. In this in vitro differentiation model, murine embryonic stem cells are cultured in methylcellulose in the presence of various hematopoietic growth factors. After 4 days of differentiation, the resulting embryoid bodies contain erythroid precursors, and by day 6 myeloid precursors have developed (21, 22) . PU.1 transcripts were present in the day 0 undifferentiated population and were upregulated at day 7 (Fig. 1B) , around the time of appearance of myeloid precursors in this culture system (21, 22) .
PU.1 and Spi-B, but Not Other Ets Family Members, Bind to the CD11b and SV40 PU.1 Binding Sites. To assess the specificity of the competitor oligonucleotides for PU.1 and/or other Ets family members, we performed electrophoretic mobility-shift assays using in vitro translated Ets family proteins and oligonucleotides containing wild-type and mutant PU.1 binding sites (Fig. 3 A-C) . The oligonucleotide encoding the wild-type CD11b promoter PU.1 binding site (CD11b-PU.1) (13) bound in vitro translated PU.1 and the closely related Spi-B protein (25) . Other Ets family members (Elf-1, Ets-1, Ets-2, and Fli-1) showed no binding activity (Fig. 3A) , nor was binding to a consensus Ets site blocked by an oligonucleotide containing the CD11b-PU.1 site (Fig. 3B ). These findings are consistent with previous studies using nuclear extracts from hematopoietic cells, in which no proteins other than PU.1 or Spi-B bound to the CD11b site (unpublished data and ref. 13 ). Furthermore, the binding of the CD11b-PU.1 double-stranded oligonucleotide to in vitro translated PU.1 proteins could be blocked with a doublestranded phosphorothioate oligonucleotide containing a PU.1 binding site from the SV40 enhancer (SV40-PU.1) (9), but not with two control oligonucleotides with a mutated PU.1 site, including the CD11b-M1 mutant (13) and a scrambled sequence containing the same base composition as the Proc. Natl. Acad. Sci. USA 91 (1994) .4 SV40-PU.1 oligonucleotide (SV40-scrambled) (9) (Fig. 3C) . A pattern of competition similar to that of PU. 1 was seen with Spi-B (data not shown).
Once we established the binding specificity of the PU.1-binding double-stranded oligonucleotides, we studied their functional activity in the U-937 monocytic cell line. U-937 cells were exposed to 7.5 gM wild-type and mutated CD11b-PU.1 oligonucleotides for 2 hr at 37TC in a humidified 5% CO2 atmosphere and then cultured for 20 hr in the presence of 30 ,uM phorbol 12-myristate 13-acetate. RNA was extracted and analyzed by RT-PCR as described above. Band intensity was quantitated on a laser densitometer. The relative CD11b mRNA signal, normalized for GAPDH, was 100lo in the control, 75% in the presence of the CD11b-M1 mutant, and 25% in the presence of CD11b-PU.1 wild-type oligonucleotide (Fig. 3D) . Both sets of wild-type PU.1-binding oligonucleotides, but not the CD11b-M1 mutant or the SV40-scrambled mutant oligonucleotides, specifically inhibited colony formation in methylcellulose of a PU.1-expressing myeloid line (U-937), but not a PU.1-negative T-cell line (Jurkat) (data not shown). (Table 1 and Fig. 4A ). Day 0 CD34+ cells were exposed to the double-stranded oligonucleotides and then plated in methylcellulose as described above. The overall effect resulted in an average 77% decrease in day 14 colony formation with the CD11b-PU.1 oligonucleotide and a 54% decrease with the SV40-PU.1 oligonucleotide. In particular the decrease of CFU-GM colony formation com- CDllb-PU.1 paring wild-type CDllb-PU.1 and Ml mutant oligonucleotides was highly statistically significant, as assessed by a paired Student t test (P < 0.001), as was the decrease in BFU-E formation (P = 0.043) ( Table 1) . When the effect of the SV40-PU.1 oligonucleotide was compared with that of SV40-scrambled, the decrease in CFU-GM and BFU-E formation was 48% (P = 0.094) and 38% (P = 0.063), respectively. None of the double-stranded oligonucleotides had toxic effects on cell viability throughout the culture period, as assessed by culturing the cells in liquid culture after exposure to the oligonucleotides. The response to the CD11b-PU.l double-stranded oligonucleotide was dependent on the amount of oligonucleotide added, with no change observed in the ratio between the number of erythroid and GM colonies formed (Fig. 4B) .
To determine the developmental stage at which PU.1 action is required, some day 0 CD34+ cells were cultured prior to the addition of competitive oligonucleotides for 2, 4, and 6 days with IL-3 and GM-CSF and subsequently incubated with the wild-type or mutated CDllb-PU.1 doublestranded oligonucleotide and plated as described above. No inhibition of colony formation was observed (data not shown).
DISCUSSION
The aim of our study was to investigate the role of the transcription factor PU. The oligonucleotides used in these studies bound specifically to PU.1 and the similar transcription factor, Spi-B, but not to other members of the Ets family. These findings support the previous observations that PU.1 and Spi-B appear to have evolved as a distinct branch of the Ets family (29) , with similarity in structure and amino acid sequence (25) , specific pattern of expression in B cells and macrophages (9) , and apparent function. It is possible that the oligonucleotides inhibit an as yet not described transcription factor that is expressed in stem cells and downregulated in myeloid cells. We think this unlikely, since no other proteins from promyelocytic nuclear extracts were observed to bind to the CD11b PU.1 site (13 
